EXEL logo

EXEL
Exelixis Inc

12,196
Mkt Cap
$12.61B
Volume
1.54M
52W High
$51.63
52W Low
$33.76
PE Ratio
16.62
EXEL Fundamentals
Price
$50.15
Prev Close
$49.65
Open
$49.75
50D MA
$45.16
Beta
0.50
Avg. Volume
2.31M
EPS (Annual)
$2.78
P/B
6.57
Rev/Employee
$2.15M
$11,425.42
Loading...
Loading...
News
all
press releases
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
Exelixis, Inc. (Nasdaq: EXEL) today announced presentations for its flagship product, CABOMETYX (cabozantinib), and its investigational oral kinase inhibitor, zanzalintinib, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 29 June 2 in Chicago. The...
News Placeholder
More News
News Placeholder
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study
Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.
News Placeholder
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
Exelixis, Inc. (Nasdaq: EXEL) today announced that the company has entered into a clinical development collaboration with Merck, known as MSD outside of the United States and Canada, to supply...
News Placeholder
Exelixis (EXEL) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
News Placeholder
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities Health Care Conference 2026...
News Placeholder
Exelixis (NASDAQ:EXEL) Price Target Raised to $50.00
Morgan Stanley increased their price objective on Exelixis from $49.00 to $50.00 and gave the company an "equal weight" rating in a report on Wednesday...
News Placeholder
Exelixis (NASDAQ:EXEL) Price Target Raised to $47.00
Stifel Nicolaus upped their price objective on Exelixis from $44.00 to $47.00 and gave the stock a "hold" rating in a research report on Wednesday...
News Placeholder
EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus
EXEL beats Q1 EPS estimates on lower costs and buybacks but misses on revenues; Cabometyx sales lag estimates as pipeline progress and new buybacks stay in focus.
News Placeholder
Wells Fargo & Company Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) Stock
Wells Fargo & Company raised their price target on shares of Exelixis from $35.00 to $40.00 and gave the company an "equal weight" rating in a research report on Wednesday...
News Placeholder
Here's Why Exelixis (EXEL) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available